Exactech Announces Successful First Surgery with New Equinoxe® Shoulder Reconstruction Prosthesis
October 07 2015 - 9:30AM
Business Wire
Exactech Enhances Focus on Revision
Arthroplasty with Pilot Launch of Three New Revision Systems in
Fourth Quarter
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone
and joint restoration products for hip, knee, shoulder and spine,
announced today the successful first surgery using its new
Equinoxe® Humeral Reconstruction Prosthesis, which is among three
new Exactech revision systems making their clinical debut. Last
week, Exactech announced the first clinical experiences with its
new revision knee and hip systems.
The humeral reconstruction prosthesis is designed to offer
flexibility for complex cases with significant proximal humeral
bone loss. It is intended for primary or revision arthroplasty
procedures and anatomic oncology procedures. It is the first
modular prosthesis cleared for significant proximal bone loss in
reverse procedures.
Orthopaedic surgeon and design team member Thomas Wright, MD, of
University of Florida Department of Orthopaedics and Rehabilitation
in Gainesville, Fla., performed the first case using the new
shoulder system.
“This novel prosthesis is an eloquent solution to a brutal
clinical problem,” Dr. Wright said. “There was really no other
viable solution for this patient. It was gratifying to see that
this implant and technique simplified a challenging case and
addressed the unique needs of this patient.”
A key feature of the humeral reconstruction prosthesis is its
modularity, with a platform stem and multiple sizes to reconstruct
the length of the humeral resection. The system’s design also
provides biomechanical advantages, several soft tissue fixation
options and rotational stability, due to unique plasma/HA coated
collars that provide additional fixation and dual offset collars
and distal stems that are designed to provide optimal fit.
“This is the culmination of years of development,” said Mark
Scarborough, MD, a design team member and chair of orthopaedic
oncology at University of Florida Department of Orthopaedics and
Rehabilitation. “The design team and corporate professionals worked
diligently to create an innovative implant that would help surgeons
improve patients’ quality of life. This first case is validation
that our design is as effective as we imagined it would be and can
dramatically impact patients’ lives.”
Exactech Chief Executive Officer David Petty said, “This is the
third first surgery with a new revision system from Exactech in the
last week. The revision shoulder system is the only one on the
market that combines a humeral reconstruction stem with a reverse
platform, extending our Equinoxe shoulder’s long history of
delivering unique solutions to improve patient outcomes.”
Exactech worked closely with a design team of experienced
revision upper extremity specialists and orthopaedic oncology
surgeons to develop this prosthesis: Pierre-Henri Flurin, MD,
Clinique du Sport (Merignac, France); Parker Gibbs, MD, University
of Florida Department of Orthopaedics and Rehabilitation
(Gainesville, Fla.); Pietro Ruggieri, MD, The Rizzoli Institute
(Bologna, Italy); Mark Scarborough, MD, University of Florida
Department of Orthopaedics and Rehabilitation (Gainesville, Fla.);
Thomas Wright, MD, University of Florida Department of Orthopaedics
and Rehabilitation (Gainesville, Fla.); and Joseph Zuckerman, MD,
NYU Hospital for Joint Diseases (New York, N.Y.).
Pilot launch is scheduled through the remainder of the year with
full market availability in the United States in 2016.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech, Inc. can be found at
http://www.exac.com. Copies of Exactech’s press releases, SEC
filings, current price quotes and other valuable information for
investors may be found at http://www.exac.com and
http://www.hawkassociates.com.
An investment profile on Exactech may be found at
http://www.hawkassociates.com/profile/exac.cfm. To receive future
releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151007005849/en/
Exactech, Inc.Investor contactsJody Phillips,
352-377-1140Executive Vice President of Finance &Chief
Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins,
305-451-1888E-mail: EXAC@hawkassociates.comorMedia contactPriscilla
Bennett, 352-377-1140Vice President, Corporate & Marketing
Communication
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Apr 2023 to Apr 2024